Solid Biosciences (SLDB) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 59.59% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -10.08% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -129.68% |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1,228.66% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -46.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.07% |
| Dec 31, 2025 | -24.47% |
| Sep 30, 2025 | -37.04% |
| Jun 30, 2025 | -53.24% |
| Mar 31, 2025 | -55.60% |
| Dec 31, 2024 | -84.64% |
| Sep 30, 2024 | -54.93% |
| Jun 30, 2024 | -1.68% |
| Mar 31, 2024 | 19.92% |
| Dec 31, 2023 | 37.62% |
| Sep 30, 2023 | -4.22% |
| Jun 30, 2023 | 0.78% |
| Mar 31, 2023 | -19.88% |
| Dec 31, 2022 | -77.10% |
| Sep 30, 2022 | -13.12% |
| Jun 30, 2022 | -34.18% |
| Mar 31, 2022 | -49.81% |
| Dec 31, 2021 | 12.69% |
| Sep 30, 2021 | 15.13% |
| Jun 30, 2021 | 1.52% |
| Mar 31, 2021 | 36.69% |
| Dec 31, 2020 | 33.31% |
| Sep 30, 2020 | 27.52% |
| Jun 30, 2020 | 28.63% |
| Mar 31, 2020 | 10.40% |
| Dec 31, 2019 | -46.12% |
| Sep 30, 2019 | -54.11% |
| Jun 30, 2019 | -47.95% |
| Mar 31, 2019 | -87.66% |
| Dec 31, 2018 | -51.31% |
| Sep 30, 2018 | -40.84% |
| Jun 30, 2018 | -58.96% |
| Mar 31, 2018 | -113,307.14% |